What is Akari Therapeutics Profitability Rank?
Akari Therapeutics has the Profitability Rank of 2. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Akari Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was %. As of today, Akari Therapeutics's Piotroski F-Score is 2.
Competitive Comparison of Akari Therapeutics's Profitability Rank
For the Biotechnology subindustry, Akari Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akari Therapeutics's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Akari Therapeutics's Profitability Rank falls into.
Akari Therapeutics Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Akari Therapeutics has the Profitability Rank of 2. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Akari Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Akari Therapeutics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Akari Therapeutics (Akari Therapeutics) Business Description
Traded in Other Exchanges
Address
75/76 Wimpole Street, London, GBR, W1G 9RT
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.
Executives
| Donald Allen Williams |
director |
C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036 |
| David Byrne |
director |
C/O AKARI THERAPEUTICS, PLC, 24 WEST 40TH STREET, 8TH FLOOR, NEW YORK NY 10018 |
| Robert M Shaw |
officer: General Counsel and Secretary |
C/O BIOTECHNOLOGY GENERAL CORP, ONE TOWER CENTER BLVD 14TH FLR, EAST BRUNSWICK NJ 08816 |
| Clive Richardson |
director, officer: COO |
C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211 |
| Rpc Pharma Ltd |
10 percent owner |
C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211 |
| Ray Prudo |
director, 10 percent owner |
C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211 |
| Stuart Ungar |
director, 10 percent owner |
C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211 |
| James Hill |
director, 10 percent owner |
C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211 |
| Mark S Cohen |
director |
C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018 |
| Allan Shaw |
director |
C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018 |
| Dov Elefant |
officer: Chief Financial Officer |
EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632 |
| Gur Roshwalb |
director, officer: Chief Executive Officer |
C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018 |
| David Sidransky |
director |
JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205 |
| Amos Eiran |
director |
C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018 |
| Lau Johnson Yiu Nam |
director |
|
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AKTX has been successfully added to your